BeyondSpring (NASDAQ:BYSI – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49, FiscalAI reports.
BeyondSpring Stock Performance
Shares of NASDAQ:BYSI traded up $0.06 during midday trading on Wednesday, reaching $1.45. The company had a trading volume of 44,334 shares, compared to its average volume of 23,555. BeyondSpring has a 1-year low of $1.21 and a 1-year high of $3.44. The firm has a market cap of $59.62 million, a price-to-earnings ratio of -9.67 and a beta of 0.41. The company has a fifty day simple moving average of $1.62 and a two-hundred day simple moving average of $1.71.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Institutional Investors Weigh In On BeyondSpring
An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp acquired a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned 0.57% of BeyondSpring at the end of the most recent quarter. 40.29% of the stock is owned by hedge funds and other institutional investors.
BeyondSpring Company Profile
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
Further Reading
- Five stocks we like better than BeyondSpring
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
